These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 23465269)

  • 1. Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy.
    Shienbaum G; Garcia Filho CA; Flynn HW; Nunes RP; Smiddy WE; Rosenfeld PJ
    Am J Ophthalmol; 2013 Jun; 155(6):1009-13. PubMed ID: 23465269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization.
    Kim JH; Chang YS; Kim JW; Kim CG; Yoo SJ; Cho HJ
    Ophthalmology; 2014 Apr; 121(4):926-35. PubMed ID: 24342019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal tissue plasminogen activator, perfluoropropane (C3F8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration.
    Papavasileiou E; Steel DH; Liazos E; McHugh D; Jackson TL
    Retina; 2013 Apr; 33(4):846-53. PubMed ID: 23400079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor with or without pneumatic displacement for submacular hemorrhage.
    Shin JY; Lee JM; Byeon SH
    Am J Ophthalmol; 2015 May; 159(5):904-14.e1. PubMed ID: 25637179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.
    Chang W; Garg SJ; Maturi R; Hsu J; Sivalingam A; Gupta SA; Regillo CD; Ho AC
    Am J Ophthalmol; 2014 Jun; 157(6):1250-7. PubMed ID: 24531021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
    Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U
    Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
    Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal ranibizumab injections with and without pneumatic displacement for treating submacular hemorrhage secondary to neovascular age-related macular degeneration.
    Cho HJ; Koh KM; Kim JH; Kim HS; Han JI; Lew YJ; Lee TG; Kim JW
    Retina; 2015 Feb; 35(2):205-12. PubMed ID: 25105310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
    Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
    Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
    Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.
    El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
    Retina; 2013 Oct; 33(9):1828-35. PubMed ID: 23615342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage.
    Mayer WJ; Hakim I; Haritoglou C; Gandorfer A; Ulbig M; Kampik A; Wolf A
    Acta Ophthalmol; 2013 May; 91(3):274-8. PubMed ID: 21952010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
    Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
    Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
    Peden MC; Suñer IJ; Hammer ME; Grizzard WS
    Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
    Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
    Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.